



News Update

www.exosomedx.com

EXOSOME DIAGNOSTICS NEWS ANNOUNCEMENT

Exosome Diagnostics Presents Clinical Performance Data for ExoDx™ *Lung(ALK)* Liquid Biopsy Test and New Data on Detection of EGFR Activating Mutations and T790M Resistance Mutation

Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new clinical performance data for its ExoDx™ *Lung(ALK)* liquid biopsy test. The data demonstrated high sensitivity and specificity of the novel exosome-based liquid biopsy test in patients with non-small cell lung cancer (NSCLC) suspected to be positive for EML4-ALK translocations. Building upon a previously presented data set, the company also presented new data showing the ability of its proprietary exosomal RNA (exoRNA) plus cell-free DNA (cfDNA) platform to detect with high sensitivity EGFR activating mutations and the EGFR T790M resistance mutation in blood plasma of patients with NSCLC.

For more information, view the [full announcement](#).

To learn more about Exosome Diagnostics, visit exosomedx.com and follow [@ExosomeDx](#).

If this message has been forwarded and you would like to receive updates, please [sign-up](#) to receive news and announcements.
If you do not want to receive these updates, you can [opt out](#).

Exosome Diagnostics, Inc. | Riverside Technology Center | 840 Memorial Drive, Suite 3 | Cambridge, MA 02139